This Article Figures Only Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Web of Science (19) Citing Articles via Google Scholar Google Scholar Articles by Torriani, F. J. Search for Related Content PubMed PubMed Citation Articles by Torriani, F. J.

CLINICAL RESEARCH: HIV AND HEART DISEASE

Endothelial Function in Human Immunodeficiency Virus-Infected Antiretroviral-Naive Subjects Before and After Starting Potent Antiretroviral Therapy

The ACTG (AIDS Clinical Trials Group) Study 5152s

Francesca J. Torriani, MD^_*,_*, Lauren Komarow, MS, Robert A. Parker, ScD, Bruno R. Cotter, MD, FACC^_*, Judith S. Currier, MD, Michael P. Dubé, MD, Carl J. Fichtenbaum, MD^||, Mariana Gerschenson, PhD^¶, Carol K.C. Mitchell, PhD^#, Robert L. Murphy, MD^_**, Kathleen Squires, MD, James H. Stein, MD, FACC^# for the ACTG 5152s Study Team

^_* University of California–San Diego, San Diego, California
Harvard School of Public Health, Boston, Massachusetts
University of California–Los Angeles, Los Angeles, California
Indiana University School of Medicine, Indianapolis, Indiana
^|| University of Cincinnati Medical Center, Cincinnati, Ohio
^¶ University of Hawaii, Honolulu, Hawaii
^# University of Wisconsin School of Medicine and Public Health, Madison, Wisconsin
^_** Northwestern University Feinberg School of Medicine, Chicago, Illinois
University of Southern California, Los Angeles, California.

Manuscript received March 27, 2008; accepted April 23, 2008.

^_* Reprint requests and correspondence: Dr. Francesca J. Torriani, University of California–San Diego Infection Prevention and Clinical Epidemiology Unit, 200 West Arbor Drive, MC 8951, San Diego, California 92103. (Email: ftorriani{at}ucsd.edu).

Objectives: This study evaluated the effects of 3 class-sparing antiretroviral therapy (ART) regimens on endothelial function in human immunodeficiency virus (HIV)-infected subjects participating in a randomized trial.

Background: Endothelial dysfunction has been observed in patients receiving ART for HIV infection.

Methods: This was a prospective, multicenter study of treatment-naive subjects who were randomly assigned to receive a protease inhibitor-sparing regimen of nucleoside reverse transcriptase inhibitors (NRTIs) + efavirenz, a non-nucleoside reverse transcriptase inhibitor-sparing regimen of NRTIs + lopinavir/ritonavir, or a NRTI-sparing regimen of efavirenz + lopinavir/ritonavir. The NRTIs were lamivudine + stavudine, zidovudine, or tenofovir. Brachial artery flow-mediated dilation (FMD) was determined by B-mode ultrasound before starting on ART, then after 4 and 24 weeks.

Results: There were 82 subjects (median age 35 years, 91% men, 54% white). Baseline CD4 cell counts and plasma HIV ribonucleic acid (RNA) values were 245 cells/mm³ and 4.8 log₁₀ copies/ml, respectively. At baseline, FMD was 3.68% (interquartile range [IQR] 1.98% to 5.51%). After 4 and 24 weeks of ART, plasma HIV RNA decreased by 2.1 and 3.0 log₁₀ copies/ml, respectively. FMD increased by 0.74% (IQR –0.62% to +2.74%, p = 0.003) and 1.48% (IQR –0.20% to +4.30%, p < 0.001), respectively, with similar changes in each arm (Kruskal-Wallis p value >0.600). The decrease in plasma HIV RNA at 24 weeks was associated with greater FMD (r_s = –0.30, p = 0.017).

Conclusions: Among treatment-naive individuals with HIV, 3 different ART regimens rapidly improved endothelial function. Benefits were similar for all ART regimens, appeared quickly, and persisted at 24 weeks.

Key Words: antiretroviral therapy • cardiovascular disease risk • endothelial function • human immunodeficiency virus

Abbreviations and Acronyms   ART = antiretroviral therapy   CVD = cardiovascular disease   FMD = flow-mediated dilation   HIV = human immunodeficiency virus   NNRTI = non-nucleoside reverse transcriptase inhibitor   NRTI = nucleoside reverse transcriptase inhibitor   NTGMD = nitroglycerin-mediated vasodilation   PI = protease inhibitor

This article has been cited by other articles:

				E. K. Hester HIV Medications: An Update and Review of Metabolic Complications Nutr Clin Pract, February 1, 2012; 27(1): 51 - 64. [Abstract] [Full Text] [PDF]

				O. Wever Pinzon, J. Silva Enciso, J. Romero, H. Makani, J. Fefer, V. Gandhi, S. Bangalore, and F. A. Chaudhry Risk Stratification and Prognosis of Human Immunodeficiency Virus-Infected Patients With Known or Suspected Coronary Artery Disease Referred for Stress Echocardiography Circ Cardiovasc Imaging, July 1, 2011; 4(4): 363 - 370. [Abstract] [Full Text] [PDF]

				T. L. Stanley and S. K. Grinspoon 10.2.4 Endocrine abnormalities in HIV infection Oxford Textbook of Endocrinology and Diabetes, July 1, 2011; 2(1): med-9780199235292-chapter - med-9780199235292-chapter. [Abstract] [Full Text]

				J. V. Baker and J. D. Lundgren Cardiovascular implications from untreated human immunodeficiency virus infection Eur. Heart J., April 2, 2011; 32(8): 945 - 951. [Abstract] [Full Text] [PDF]

				K. E. Mondy, J. Gottdiener, E. T. Overton, K. Henry, T. Bush, L. Conley, J. Hammer, C. C. Carpenter, E. Kojic, P. Patel, et al. High Prevalence of Echocardiographic Abnormalities among HIV-infected Persons in the Era of Highly Active Antiretroviral Therapy Clinical Infectious Diseases, February 1, 2011; 52(3): 378 - 386. [Abstract] [Full Text] [PDF]

				E. C. Seaberg, L. Benning, A. R. Sharrett, J. M. Lazar, H. N. Hodis, W. J. Mack, M. J. Siedner, J. P. Phair, L. A. Kingsley, and R. C. Kaplan Association Between Human Immunodeficiency Virus Infection and Stiffness of the Common Carotid Artery Stroke, October 1, 2010; 41(10): 2163 - 2170. [Abstract] [Full Text] [PDF]

				C. D. MALVESTUTTO and J. A. ABERG Coronary heart disease in people infected with HIV Cleveland Clinic Journal of Medicine, August 1, 2010; 77(8): 547 - 556. [Abstract] [Full Text] [PDF]

				M. P. Dube and F. R. Sattler Inflammation and Complications of HIV Disease The Journal of Infectious Disease, June 15, 2010; 201(12): 1783 - 1785. [Full Text] [PDF]

				B. Taiwo, C. Hicks, and J. Eron Unmet therapeutic needs in the new era of combination antiretroviral therapy for HIV-1 J. Antimicrob. Chemother., June 1, 2010; 65(6): 1100 - 1107. [Abstract] [Full Text] [PDF]

				H. M. Johnson, L. K. Gossett, M. E. Piper, S. E. Aeschlimann, C. E. Korcarz, T. B. Baker, M. C. Fiore, and J. H. Stein Effects of Smoking and Smoking Cessation on Endothelial Function: 1-Year Outcomes From a Randomized Clinical Trial J. Am. Coll. Cardiol., May 4, 2010; 55(18): 1988 - 1995. [Abstract] [Full Text] [PDF]

				P. Y. Hsue, P. W. Hunt, J. E. Ho, H. H. Farah, A. Schnell, R. Hoh, J. N. Martin, S. G. Deeks, and A. F. Bolger Impact of HIV Infection on Diastolic Function and Left Ventricular Mass Circ Heart Fail, January 1, 2010; 3(1): 132 - 139. [Abstract] [Full Text] [PDF]

				J. E Ho and P. Y Hsue Cardiovascular manifestations of HIV infection Heart, July 15, 2009; 95(14): 1193 - 1202. [Full Text] [PDF]